25/07/2022 (Agence Europe) – The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) announced on 22 July that it had recommended the extension of the use of the Spikevax vaccine following its meeting from 18 to 21 July. The EMA recommends extending the use of the messenger RNA vaccine produced by Moderna as a booster dose against Covid-19 to adolescents aged 12 to 17 years. The Committee also approved the inclusion in the product information of the fact that the stability of Spikevax vaccine for 12 months, when stored under the appropriate conditions, had been proven. At this meeting, the EMA approved a new production site for the finished product of Spikevax vaccine in Madrid, Spain. (EV)